Piper Sandler raised the firm’s price target on Fulcrum Therapeutics (FULC) to $16 from $12.50 and keeps an Overweight rating on the shares. The firm notes Fulcrum will report 20mg pociredir data at ASH in December. Fulcrum disclosed that baseline HbF in the 12 patients enrolled was 7.1% mean. Piper is confident that 20mg pociredir will outperform the 12mg cohort across performance measures.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC: